Immunotherapy of Colon Cancer

Alexander Stein; Gunnar Folprecht

doi:10.1159/000488918

Immunotherapy of Colon Cancer

Standard

Immunotherapy of Colon Cancer. / Stein, Alexander; Folprecht, Gunnar.

In: ONCOL RES TREAT, Vol. 41, No. 5, 2018, p. 282-285.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stein, A & Folprecht, G 2018, 'Immunotherapy of Colon Cancer', ONCOL RES TREAT, vol. 41, no. 5, pp. 282-285. https://doi.org/10.1159/000488918

APA

Stein, A., & Folprecht, G. (2018). Immunotherapy of Colon Cancer. ONCOL RES TREAT, 41(5), 282-285. https://doi.org/10.1159/000488918

Vancouver

Stein A, Folprecht G. Immunotherapy of Colon Cancer. ONCOL RES TREAT. 2018;41(5):282-285. https://doi.org/10.1159/000488918

Bibtex

@article{dde6b025e8ab42da94302de6e5b3ea91,

title = "Immunotherapy of Colon Cancer",

abstract = "In contrast to other tumour types inhibitors of PD-1/-L1 or CTLA 4 have not yet shown relevant efficacy in unselected colorectal cancer. Based on the high mutational burden, deficient mismatch repair (dMMR) or microsatellite instable (MSI-H) tumours are yet the only subgroup, which is amenable to checkpoint inhibition. These tumours show relevant and durable responses in the refractory setting by PD-1/-L1 +/- CTLA 4 inhibition. Thus, ongoing phase 3 trials in this subgroup evaluate immunotherapy in the adjuvant setting as well as in the first line metastatic setting with or without chemotherapy. For the by far larger subgroup of non-dMMR/MSI-H patients (95% in the metastatic setting) combination regimen are urgently required, either with chemotherapy and/or molecular targeting drugs, local ablative treatments or other immunotherapeutic agents (e.g. CEA-TCB).",

keywords = "Journal Article",

author = "Alexander Stein and Gunnar Folprecht",

note = "{\textcopyright} 2018 S. Karger GmbH, Freiburg.",

year = "2018",

doi = "10.1159/000488918",

language = "English",

volume = "41",

pages = "282--285",

journal = "ONCOL RES TREAT",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "5",

}

RIS

TY - JOUR

T1 - Immunotherapy of Colon Cancer

AU - Stein, Alexander

AU - Folprecht, Gunnar

PY - 2018

Y1 - 2018

N2 - In contrast to other tumour types inhibitors of PD-1/-L1 or CTLA 4 have not yet shown relevant efficacy in unselected colorectal cancer. Based on the high mutational burden, deficient mismatch repair (dMMR) or microsatellite instable (MSI-H) tumours are yet the only subgroup, which is amenable to checkpoint inhibition. These tumours show relevant and durable responses in the refractory setting by PD-1/-L1 +/- CTLA 4 inhibition. Thus, ongoing phase 3 trials in this subgroup evaluate immunotherapy in the adjuvant setting as well as in the first line metastatic setting with or without chemotherapy. For the by far larger subgroup of non-dMMR/MSI-H patients (95% in the metastatic setting) combination regimen are urgently required, either with chemotherapy and/or molecular targeting drugs, local ablative treatments or other immunotherapeutic agents (e.g. CEA-TCB).

AB - In contrast to other tumour types inhibitors of PD-1/-L1 or CTLA 4 have not yet shown relevant efficacy in unselected colorectal cancer. Based on the high mutational burden, deficient mismatch repair (dMMR) or microsatellite instable (MSI-H) tumours are yet the only subgroup, which is amenable to checkpoint inhibition. These tumours show relevant and durable responses in the refractory setting by PD-1/-L1 +/- CTLA 4 inhibition. Thus, ongoing phase 3 trials in this subgroup evaluate immunotherapy in the adjuvant setting as well as in the first line metastatic setting with or without chemotherapy. For the by far larger subgroup of non-dMMR/MSI-H patients (95% in the metastatic setting) combination regimen are urgently required, either with chemotherapy and/or molecular targeting drugs, local ablative treatments or other immunotherapeutic agents (e.g. CEA-TCB).

KW - Journal Article

U2 - 10.1159/000488918

DO - 10.1159/000488918

M3 - SCORING: Journal article

C2 - 29705788

VL - 41

SP - 282

EP - 285

JO - ONCOL RES TREAT

JF - ONCOL RES TREAT

SN - 2296-5270

IS - 5

ER -